16 giugno 2022 – The European Medicines Agency (EMA) started a rolling review for a version of Comirnaty adapted to provide better protection against SARS-CoV-2. The review will initially focus on chemistry, manufacturing, and controls (CMC), which relate to the manufacturing of the vaccine.

For more information, see here.